Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenyankangfu tablets versus losartan for proteinuria in primary glomerulonephritis and diabetic kidney disease
ChiCTR-TRC-13003612Phase 4Suspended
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Shenyan Kangfu Tablet and losartan in primary glomerulonephritis and diabetic glomerulosclerosis (5 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: 24-hour proteinuria and white blood cell count. Started Dec 2013; status: suspended.
02
Drugs
Shenyan Kangfu Tabletlosartan
03
Conditions
primary glomerulonephritisdiabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR-TRC-13003612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003612.